• Bavarian Nordic A/S, of Kvistgard, Denmark, reported that it completed an offering of about 12.9 million shares and netted about $124.9 million to support development of its prostate cancer vaccine candidate Prostvac, particularly its pivotal Phase III trial. (See BioWorld Today, April 5, 2011.)